A semiempirical model of tumor pretargeting

Bioconjugate Chemistry

Volumn 19, Issue 11, 2008, Pages 2095-2104

  Liu, Guozheng ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IN-VIVO; SEMI-EMPIRICAL; SEMIEMPIRICAL MODELS;

ANTIBODIES;

ANTIBODY; BIOTIN; HAPTEN ANTIBODY; OLIGOMER; STREPTAVIDIN;

AFFINITY LABELING; ANTIBODY AFFINITY; ANTIBODY LABELING; ANTIGEN ANTIBODY REACTION; BIOACCUMULATION; DRUG TARGETING; EFFECTOR CELL; HUMAN; IMMUNOGENICITY; ISOTOPE LABELING; MATHEMATICAL MODEL; NONHUMAN; REVIEW; SEMIEMPIRICAL MODEL; TUMOR;

EID: 56749179687     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc8002748     Document Type: Review

References (112)

1. Corneillie, T. M., Whetstone, P. A., and Meares, C. F. (2006) Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting. J. Inorg. Biochem. 100, 882-890.
2. Sharkey, R. M., and Goldenberg, D. M. (2006) Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest. 24, 82-97.
3. Goldenberg, D. M., and Sharkey, R. M. (2006) Advances in cancer therapy with radiolabeled monoclonal antibodies. Q. J. Nucl. Med. Mol. Imaging 50, 248-264.
4. Sharkey, R. M., Karacay, H., Cardillo, T. M., Chang, C. H., McBride, W. J., Rossi, E. A., Horak, I. D., and Goldenberg, D. M. (2005) Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin. Cancer Res. 11, 7109s-7121s.
5. Sharkey, R. M., and Goldenberg, D. M. (2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46, 115s-127s.
6. Bethge, W. A., and Sandmaier, B. M. (2005) Targeted cancer therapy using radiolabeled monoclonal antibodies. Technol. Cancer Res. Treat. 4, 393-405.
7. Govindan, S. V., Griffiths, G. L., Hansen, H. J., Horak, I. D., and Goldenberg, D. M. (2005) Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol. Cancer Res. Treat. 4, 375-391.
8. DeNardo, S. J. (2005) Radioimmunodetection and therapy of breast cancer. Semin. Nucl. Med. 35, 143-151.
9. Gruaz-Guyon, A., Janevik-Ivanovska, E., Raguin, O., De Labriolle-Vaylet, C., and Barbet, J. (2001) Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q. J. Nucl. Med. 45, 201-206.
10. Mulford, D. A., Scheinberg, D. A., and Jurcic, J. G. (2005) The promise of targeted α-particle therapy. J. Nucl. Med 46, 199s-204s.
11. Reilly, R. M. (2006) Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. J. Nucl. Med. 47, 196-199.
12. Meredith, R. F., and Buchsbaum, D. J. (2006) Pretargeted radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 66, 57s-59s.
13. DeNardo, G. L., Sysko, V. V., and DeNardo, S. J. (2006) Cure of incurable lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 66, 46s-56s.
14. Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., and Chatal, J. F. (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24, 823-834.
15. Van de Wiele, C., Revets, H., and Mertens, N. (2004) Advances and prospects. Q. J. Nucl. Med. Mol. Imaging 48, 317-325.
16. Goldenberg, D. M. (2003) Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol. Immunother. 52, 281-96.
17. Fritzberg, A. R. (1998) Antibody pretargeted radiotherapy: a new approach and a second chance. J. Nucl. Med. 39 (2), 36N.
18. Chang, C. H., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., Hansen, H. J., Chatal, J. F., Barbet, J., and Goldenberg, D. M. (2002) Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol. Cancer Ther. 1, 553-563.
19. Goldenberg, D. M., Rossi, E. A., Sharkey, R. M., McBride, W. J., and Chang, C. H. (2008) Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J. Nucl. Med. 49, 158-163.
20. Sharkey, R. M., Karacay, H., McBride, W. J., Rossi, E. A., Chang, C. H., and Goldenberg, D. M. (2007) Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update. Clin. Cancer Res. 13, 5577s-5585s.
21. Gruaz-Guyon, A., Raguin, O., and Barbet, J. (2005) Recent advances in pretargeted radioimmunotherapy. Curr. Med. Chem. 12, 319-338.
22. Boerman, O. C., van Schaijk, F. G., Oyen, W. J., and Corstens, F. H. (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med. 44, 400-411.
23. Goodwin, D. A., and Meares, C. F. (2001) Advances in pretargeting biotechnology. Biotechnol. Adv. 19, 435-450.
24. McQuarrie, S. A., Xiao, Z., Miller, G. G., Mercer, J. R., and Suresh, M. R. (2001) Modern trends in radioimmunotherapy of cancer: pretargeting strategies for the treatment of ovarian cancer. Q. J. Nucl. Med. 45, 160-166.
25. Barbet, J., Kraeber-Bodéré, F., Vuillez, J. P., Gautherot, E., Rouvier, E., and Chatal, J. F. (1999) Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother. Radiopharm. 14, 153-166.
26. Wilbur, D. S., Pathare, P. M., Hamlin, D. K., Stayton, P. S., To, R., Klumb, L. A., Buhler, K. R., and Vessella, R. L. (1999) Development of new biotin/streptavidin reagents for pretargeting. Biomol. Eng. 16, 113-118.
27. Stoldt, H. S., Aftab, F., Chinol, M., Paganelli, G., Luca, F., Testori, A., and Geraghty, J. G. (1997) Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur. J. Cancer 33, 186-192.
28. Goodwin, D. A., and Meares, C. F. (1997) Pretargeting: general principles. Cancer 80, 2675s-2680s.
29. Goodwin, D. A. (1995) Tumor pretargeting: almost the bottom line. J. Nucl. Med. 36, 876-879.
30. Liu, G., He, J., Dou, S., Gupta, S., Rusckowski, M., and Hnatowich, D. J. (2005) Further investigations of morpholino pretargeting in mice - establishing quantitative relations in tumor. Eur. J. Nucl. Med. Mol. Imaging 32, 1115-1123.
31. Liu, G., Dou, S., He, J., Liu, X., Rusckowski, M., and Hnatowich, D. J. (2007) Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur. J. Nucl. Med. Mol. Imaging 34, 237-246.
32. Liu, G., Dou, S., Preterms, P. H., Liu, X., Rusckowski, M., and Hnatowich, D. J. (2008) Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur. J. Nucl. Med. Mol. Imaging 35, 272-280.
33. Liu, G., Dou, S., Rusckowski, M., and Hnatowich, D. J. (2008) An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol. Cancer Ther. 7, 1025-1032.
34. Karacay, H., Brard, P. Y., Sharkey, R. M., Chang, C. H., Rossi, E. A., McBride, W. J., Ragland, D. R., Horak, I. D., and Goldenberg, D. M. (2005) Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin. Cancer Res. 11, 7879-7885.
35. Sharkey, R. M., Cardillo, T. M., Rossi, E. A., Chang, C. H., Karacay, H., McBride, W. J., Hansen, H. J., Horak, I. D., and Goldenberg, D. M. (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat. Med. 11, 1250-1255.
36. Pagel, J. M., Hedin, N., Subbiah, K., Meyer, D., Mallet, R., Axworthy, D., Theodore, L. J., Wilbur, D. S., Matthews, D. C., and Press, O. W. (2003) Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101, 2340-2348.
37. Subbiah, K., Hamlin, D. K., Pagel, J. M., Wilbur, D. S, Meyer, D. L., Axworthy, D. B, Mallett, R. W., Theodore, L. J., Stayton, P. S., and Press, O. W. (2003) Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J. Nucl. Med. 44, 437-445.
38. Magnani, P., Paganelli, G., Modorati, G., Zito, F., Songini, C., Sudati, F., Koch, P., Maecke, H. R., Brancato, R., Siccardi, A. G., and Fazio, F. (1996) Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J. Nucl. Med. 37, 967-971.
39. Sung, C., and van Osdol, W. W. (1995) Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J. Nucl. Med. 36, 867-876.
40. Wu, A. M. (2001) Tools for pretargeted radioimmunotherapy. Cancer Biother. Radiopharm. 16, 103-108.
41. Reardan, D. T., Meares, C. F., Goodwin, D. A., McTigue, M., David, G. S., Stone, M. R., Leung, J. P., Bartholomew, R. M., and Frincke, J. M. (1985) Antibodies against metal chelates. Nature 316 (6025), 265-268.
42. Goodwin, D. A., Meares, C. F., McTigue, M., et al. (1986) Rapid localization of haptens in sites containing previously administrated antibody for immunoscintigraphy with short half-life tracers [abstract]. J. Nucl. Med. 27, 959s.
43. Hnatowich, D. J., Virzi, F., and Rusckowski, M. (1987) Investigations of avidin and biotin for imaging applications. J. Nucl. Med. 28, 1294-1302.
44. Kuijpers, W. H., Bos, E. S., Kaspersen, F. M., Veeneman, G. H., and van Boeckel, C. A. (1993) Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconjugate Chem. 4, 94-102.
45. Rusckowski, M., Qu, T., Chang, F., and Hnatowich, D. J. (1997) Pretargeting using peptide nucleic acid (PNA). Cancer 80, 2699-2705.
46. 99mTc-labeled morpholino, a DNA analog. J. Nucl. Med. 43, 384-391.
47. Boerman, O. C., van Eerd, J., Oyen, W. J., and Corstens, F. H. (2001) A 3-step pretargeting strategy to image infection. J. Nucl. Med. 42, 1405-1411.
48. Kranenborg, M. H., Oyen, W. J., Corstens, F. H., Oosterwijk, E., van der Meer, J. W., and Boerman, O. C. Rapid imaging of experimental infection with technetium-99m-DTPA after anti-DTPA monoclonal antibody priming. J. Nucl. Med. 38, 901-906.
49. Goodwin, D. A., Meares, C. F., McCall, M. J., McTigue, M., and Chaovapong, W. (1988) Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J. Nucl. Med. 29, 226-234.
50. Mirallie, E., Sai-Maurel, C., Faivre-Chauvet, A., Regenet, N., Chang, C. H., Goldenberg, D. M., Chatal, J. F., Barbet, J., and Thedrez, P. (2005) Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. Eur. J. Nucl. Med. Mol. Imaging 32, 901-909.
51. Le Doussal, J. M., Gruaz-Guyon, A., Martin, M., Gautherot, E., Delaage, M., and Barbet, J. (1990) Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res. 50, 3445-3452.
52. Goodwin, D. A., Meares, C. F., McTigue, M., Chaovapong, W., Diamanti, C. I., Ransone, C. H., and McCall, M. J. (1992) Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J. Nucl. Med. 33, 2006-2013.
53. 90Y radioimmunotherapy. Cancer Res. 54, 5937-5946.
54. Kranenborg, M. H., Boerman, O. C., Oosterwijk-Wakka, J. C., de Weijert, M. C., Corstens, F. H., and Oosterwijk, E. (1998) Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies. Int. J Cancer. 75, 74-80.
55. Paganelli, G., Riva, P., Deleide, G., Clivio, A., Chiolerio, F., Scassellati, G. A., Malcovati, M., and Siccardi, A. G. (1988) In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int. J. Cancer Suppl. 2, 121-125.
56. Paganelli, G., Pervez, S., Siccardi, A. G., Rowlinson, G., Deleide, G., Chiolerio, F., Malcovati, M., Scassellati, G. A., and Epenetos, A. A. (1990) Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int. J. Cancer 45, 1184-1189.
57. Pimm, M. V., Fells, H. F., Perkins, A. C., and Baldwin, R. W. (1988) Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody. Nucl. Med. Commun. 9, 931-941.
58. Khawli, L. A., Alauddin, M. M., Miller, G. K., and Epstein, A. L. (1993) Improved immunotargeting of tumor with biotinlated monoclonal antibodies and radiolabeled streptavidin. Antibody Immunoconj. Radiopharm. 6, 13-27.
59. Saga, T., Weinstein, J. N., Jeong, J. M., Heya, T., Lee, J. T., Le, N., Paik, C. H., Sung, C., and Neumann, R. D. (1994) Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 54, 2160-2165.
60. Yao, Z., Zhang, M., Kobayashi, H., Sakahara, H., Nakada, H., Yamashina, I., and Konishi, J. (1995) Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J. Nucl. Med. 36, 837-841.
61. Rusckowski, M., Fritz, B., and Hnatowich, D. J. (1992) Localization of infection using streptavidin and biotin: an alternative to nonspecific polyclonal immunoglobulin. J. Nucl. Med. 33, 1810-1815.
62. Rusckowski, M., Fogarasi, M., Fritz, B., and Hnatowich, D. J. (1997) Effect of endogenous biotin on the applications of streptavidin and biotin in mice. Nucl. Med. Biol. 24, 263-268.
63. Sharkey, R. M., Karacay, H., Griffiths, G. L., Behr, T. M., Blumenthal, R. D., Mattes, M. J., Hansen, H. J., and Goldenberg, D. M. (1997) Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjugate Chem. 8, 595-604.
64. Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., Breitz, H., Adams, G. P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, I. D., and Weiner, L. M. (2000) Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6, 406-414.
65. Caliceti, P., Chinol, M., Roldo, M., Veronese, F. M., Semenzato, A., Salmaso, S., and Paganelli, G. (2002) Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting. J. Controlled Release 83, 97-108.
66. Sinitsyn, V. V., Mamontova, A. G., Checkneva, Y. Y., Shnyra, A. A., and Domogataky, S. P. (1989) Rapid blood clearance of biotinylatedIgG after infusionof avidin. J. Nucl. Med. 30, 66-69.
67. Virzi, F., Fritz, B., Rusckowski, M., Gionet, M., Misra, H., and Hnatowich, D. J. (1991) New indium-111 labeled biotin derivatives for improved immunotargeting. Int. J. Rod. Appl. Instrum. B 18, 719-726.
68. Hnatowich, D. J., Fritz, B., Virzi, F, Mardirossian, G., and Rusckowski, M. (1993) Improved tumor localization with (strept)avidin and labeled biotin as a substitute for antibody. Nucl. Med. Biol. 20, 189-195.
69. 111In-DTPA-biocytin. Nucl. Med. Biol. 23, 459-466.
70. Goodwin, D. A., Meares, C. F., and Osen, M. (1998) Biological properties of biotin-chelate conjugates for retargeted diagnosis and therapy with the avidin/biotin system. J. Nucl. Med. 39, 1813-1818.
71. Casalini, P., Luison, E., Menard, S., Colnaghi, M. I., Paganelli, G., and Canevari, S. (1997) Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J. Nucl. Med. 38, 1378-1381.
72. Muzykantov, V. R., Christofidou-Solomidou, M., Balyasnikova, I., Harshaw, D. W., Schultz, L., Fisher, A. B., and Albelda, S. M. (1999) Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc. Natl. Acad Sci. U.S.A. 96, 2379-2384.
73. Chinol, M., Paganelli, G., Sudati, F., Meares, C., and Fazio, F. (1997) Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting. Nucl. Med. Commun. 18, 176-182.
74. 111In-DTPA- biotin. Nucl. Med. Biol. 25, 95-99.
75. Kassis, A. I., Jones, P. L., Matalka, K. Z., and Adelstein, S. J. (1996) Antibody-dependent signal amplification in tumor xenografts after pretreatment with biotinylated monoclonal antibody and avidin or streptavidin. J. Nucl. Med. 37, 343-352.
76. Bos, E. S., Kuijpers, W. H., Meesters-Winters, M., Pham, D. T., de Haan, A. S., van Doornmalen, A. M., Kaspersen, F. M., van Boeckel, C. A., and Gougeon-Bertrand, F. (1994) In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res. 54, 3479-3486.
77. Hnatowich, D. J. (1997) Pharmacokinetic considerations in the development of oligomers as radiopharmaceuticals. Q. J. Nucl. Med. 41, 91-100.
78. Wang, Y., Chang, F., Zhang, Y., Liu, N., Liu, G., Gupta, S., Rusckowski, M., and Hnatowich, D. J. (2001) Pretargeting with amplification using polymeric peptide nucleic acid (PNA). Bioconjugate Chem. 12, 807-816.
79. Summerton, J., and Weller, D. (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187-195.
80. He, J., Liu, G., Vanderheyden, J. L., Dou, S., Rusckowski, M., and Hnatowich, D. J. (2005) Affinity enhancement bivalent morpholino for pretargeting: initial evidence by surface plasmon resonance. Bioconjugate Chem. 16, 338-345.
81. He, J., Liu, X., Zhang, S., Liu, G., and Hnatowich, D. J. (2005) Affinity enhancement bivalent morpholinos for pretargeting: surface plasmon resonance studies of molecular dimensions. Bioconjugate Chem. 16, 1098-1104.
82. He, J., Liu, G., Gupta, S., Zhang, Y., Vanderheyden, J. L., Rusckowski, M., and Hnatowich, D. J. (2004) Amplification targeting: amodified pretargeting approach with potential for signal amplification-proof of a concept. J. Nucl. Med. 45, 1087-1095.
83. Chen, X., Dou, S., Liu, G., Liu, X., Wang, Y., Chen, L., Rusckowski, M., and Hnatowich, D. J. (2008) Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjugate Chem. 19, 1518-1525.
84. 99mTc-morpholinos in mice. Q. J. Nucl. Med. 46, 233-243.
85. Liu, G., Liu, C., Zhang, S., He, J., Liu, N., Gupta, N., Rusckowski, M., and Hnatowich, D. J. (2003) Investigations of technetium-99m morpholino pretargeting in mice. Nucl. Med. Commun. 24, 697-705.
86. Liu, G., He, J., Dou, S., Gupta, S., Vanderheyden, J. L., Rusckowski, M., and Hnatowich, D. J. (2004) Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur. J. Nucl. Med. Mol. Imaging 31, 417-424.
87. 188Re radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analog. Clin. Cancer Res. 12, 4958-1964.
88. Bagshawe, K. D., Sharma, S. K., and Begent, R. H. (2004) Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin. Biol. Ther. 4, 1777-1789.
89. Liu, G., Dou, S., Yin, D., Squires, S., Liu, X., Wang, Y., Rusckowski, M., and Hnatowich, D. J. (2007) A novel pretargeting method for measuring antibody internalization in tumor cells. Cancer Biother. Radiopharm. 22, 33-39.
90. Yuan, F., Baxter, L. T., and Jain, R. K. (1991) Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res. 51, 3119-3130.
91. Sung, C., and van Osdol, W. W. (1995) Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J. Nucl. Med. 36, 867-76.
92. Sung, C., van Osdol, W. W., Saga, T., Neumann, R. D, Dedrick, R. L, and Weinstein, J. N. (1994) Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res. 54, 2166-2175.
93. van Osdol, W. W., Sung, C., Dedrick, R. L., and Weinstein, J. N. (1993) A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. J. Nucl. Med. 34, 1552-1564.
94. Sharkey, R. M., Karacay, H., Richel, H., McBride, W. J., Rossi, E. A., Chang, K., Yeldell, D., Griffiths, G. L., Hansen, H. J., and Goldenberg, D. M. (2003) Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin. Cancer Res. 9, 3897s-913s.
95. Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F., Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. (2000) Cure of human carcinoma xenografts by a single dosage of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. U.S.A. 97, 1802-1807.
96. Schultz, J., Lin, Y., Sanderson, J., Zuo, Y., Stone, D., Mallett, R., Wilbert, S., and Axworthy, D. (2000) A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 60, 6663-6669.
97. Goshorn, S., Sanderson, J., Axworthy, D., Lin, Y., Hylarides, M., and Schultz, J. (2001) Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer Biother. Radiopharm. 16, 109-123.
98. 90Y-labeled 1,4,7,10-tetraazacyclododecane- N,N′,N″,N″-tetraacetic acid (DOTA)-biotin. Cancer Res. 62, 5755-5760.
99. Pagel, J. M., Lin, Y., Hedin, N., Pantelias, A., Axworthy, D., Stone, D., Hamlin, D. K., Wilbur, D. S., and Press, O. W. (2006) Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood 108, 328-336.
100. Lin, Y., Pagel, J. M., Axworthy, D., Pantelias, A., Hedin, N., and Press, O. W. (2006) A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res. 66, 3884-3892.
101. 90Y-DOTA-biotin. J. Nucl. Med. 41, 131-140.
102. Forera, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J., Goris, M. L., Picozzi, V. J., Axworthy, D. B., Breitz, H. B., Sims, R. B., Ghalie, R. G., Shen, S., and Meredith, R. F. (2004) Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104, 227-236.
103. Sharkey, R. M., Juweid, M., Shevitz, J., Behr, T., Dunn, R., Swayne, L. C., Wong, G. Y., Blumenthal, R. D., Griffiths, G. L., Siegel, J. A., et al. (1995) Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res. 55, 5935s-5945s.
104. Kraeber-Bodere, F., Faivre-Chauvet, A., Ferrer, L., Vuillez, J. P., Brard, P. Y., Rousseau, C., Resche, I., Devillers, A., Laffont, S., Bardies, M., Chang, K., Sharkey, R. M., Goldenberg, D. M., Chatal, J. F., and Barbet, J. (2003) Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin. Cancer Res. 9, 3973s-3981s.
105. Kraeber-Bodere, F., Rousseau, C., Bodet-Milin, C., Ferrer, L., Faivre-Chauvet, A., Campion, L., Vuillez, J. P., Devillers, A., Chang, C. H., Goldenberg, D. M., Chatal, J. F., and Barbet, J. (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J. Nucl. Med. 47, 247-255.
106. Karacay, H., Sharkey, R. M., McBride, W. J., Griffiths, G. L., Qu, Z., Chang, K., Hansen, H. J., and Goldenberg, D. M. (2002) Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. Bioconjugate Chem. 13, 1054-1070.
107. Cardillo, T. M., Karacay, H., Goldenberg, D. M., Yeldell, D., Chang, C. H., Modrak, D. E., Sharkey, R. M., and Gold, D. V. (2004) Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin. Cancer Res. 10, 3552-3561.
108. Rossi, E. A., Sharkey, R. M., McBride, W., Karacay, H., Zeng, L., Hansen, H. J., Goldenberg, D. M., and Chang, C. H. (2003) Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin. Cancer Res. 9, 3886s-3896s.
109. van Schaijk, F. G., Boerman, O. C., Soede, A. C., McBride, W. J., Goldenberg, D. M., Corstens, F. H., and Oosterwijk, E. (2005) Comparison of IgG and F(ab′)2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes. Eur. J. Nucl. Med. Mol. Imaging 32, 1089-1095.
110. He, J., Liu, G., Dou, S., Gupta, S., Rusckowski, M., and Hnatowich, D. J. (2007) An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjugate Chem. 18, 983-988.
111. van Schaijk, F. G., Oosterwijk, E., Molkenboer-Kuenen, J. D., Soede, A. C., McBride, B. J., Goldenberg, D. M., Oyen, W. J., Corstens, F. H., and Boerman, O. C. (2005) Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J. Nucl. Med. 46, 495-501.
112. van Schaijk, F. G., Broekema, M., Oosterwijk, E., van Eerd, J. E., McBride, B. J., Goldenberg, D. M., Corstens, F. H., and Boerman, O. C. (2005) Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J. Nucl. Med. 46, 1016-1022.